CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation

Sponsor
Ruijin Hospital
Study ID
NCT07672964
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Haplo-identical HCT
  • Hematologic Malignancy

Eligibility Criteria

Sex
ALL
Age
14 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • CD45RA-depleted DLI — BIOLOGICAL
    CD45RA Depleted DLI by ex vivo CliniMACS® prepared from mononuclear cell leukapheresis

Study Details

The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant. It will also learn about the safety of this treatment. The main questions it aims to answer are: Does this treatment lower the chance of getting serious viral infections after transplant? What medical problems do patients have when receiving this treatment?

Key Dates

First listed
Jun 29, 2026
Start date
Jul 1, 2026
Status verified
Jun 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Prevention Group
    Prophylactic CD45RA-depleted DLI

Primary Outcome Measure

Cumulative Incidence of Overall Viral Infection After CD45RA-Depleted DLI [ Time Frame: Up to 3 months after the first CD45RA-depleted DLI, assessed at Days 14, 28, 60, and 90. ]

Related Studies